Coherus Unveils Exciting Toripalimab Findings at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on M… Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemotherapy During the 2023 AACR-NCI-EORTC International Conference, Coherus Biosciences presented groundbreaking data on the efficacy of Toripalimab in activating…